血清碱性磷酸酶在去势抵抗性前列腺癌伴骨转移化疗中的临床意义-现代医学

血清碱性磷酸酶在去势抵抗性前列腺癌伴骨转移化疗中的临床意义

单位：上海市静安区市北医院泌尿外科, 上海 200443

分类号：R737.25

出版年·卷·期（页码）：2019·47·第八期（966-969）

摘要：

目的：评估血清碱性磷酸酶（ALP）在去势抵抗性前列腺癌（CRPC）伴骨转移患者化疗中的临床意义。方法：回顾性分析30例CRPC伴骨转移患者，经多西他赛化疗后，检测血清ALP及骨痛评分（VAS）、前列腺特异性抗原（PSA）、生活质量（ECOG）评分等，统计学方法分析血清ALP等指标的变化。结果：30例患者均经过1年（16个疗程）的多西他赛治疗，患者血清ALP下降率100%，治疗前后差异显著（P<0.000 1），血清PSA下降率53.3%，治疗后PSA也明显下降（P<0.000 1）；同时，骨痛评分明显下降（P<0.000 1），患者生活质量明显改善（P<0.000 1）。结论：多西他赛治疗CRPC伴骨转移患者后，血清ALP明显下降，血清ALP是CRPC伴骨转移化疗中良好的监测指标，其敏感性优于血清总PSA。

Objective:To evaluate the clinical significance of serum alkaline phosphatase in castration-resistant prostate cancer with chemotherapy for bone metastasis.Methods:We performed a retrospective study in 30 castration-resistant prostate cancer (CRPC) with bone metastasis patients who underwent docetaxel chemotherapy. Serum alkaline phosphatase (ALP) and bone pain score (evaluated by visual analogue scale/score, VAS), prostate-specific antigen(PSA), the score of quality of life (evaluated by eastern cooperative oncology group, ECOG) were observed and the changes of these parameters were analyzed. Results:All 30 patients completed one year (16 courses of treatment) docetaxel chemotherapy. Serum ALP of all 30 patients decreased significantly after chemotherapy (P<0.000 1). However, the reduction rate of serum PSA was 53.3% and the results also reached the statistical significance (P<0.000 1). Meanwhile, the bone pain score declined sharply and the score of quality of life was significantly improved.Conclusion:Serum ALP decreased dramatically after docetaxel chemotherapy in CRPC with bone metastasis patients. Serum ALP could be served as a good monitoring indicator for evaluating the effectiveness of chemotherapy in CRPC with bone metastasis patients and its performance was superior to serum PSA.

参考文献：

[1] SIEGEL R L,MILLER K D,JEMAL A.Cancer statistics,2018[J].CA Cancer J Clin,2018,68(1):7-30.
[2] JEMAL A,BRAY F,CENTER M M,et al.Forman D.Global cancer statistics[J].CA Cancer J Clin,2011,61(2):69-90.
[3] CHEN W,ZHENG R,BAADE P D,et al.Cancer statistics in China,2015[J].CA Cancer J Clin,2016,66(2):115-132.
[4] PEYROMAURE M,DEBRE B,MAO K,et al.Management of prostate cancer in China:a multicenter report of 6 institutions[J].J Urol,2005,174(5):1794-1797.
[5] METWALLI A R,ROSNER I L,CULLEN J,et al.Elevated alkaline phosphatase velocity strongly predicts overall survival and the risk of bone metastases in castrate-resistant prostate cancer[J].Urol Oncol-Semin Ori,2014,32(6):761-768.
[6] HAN K S,HONG S J.Serum alkaline phosphatase differentiates protate-specific antigen flare from early disease progression after docetaxel chemotherapy in castration-resistant prostate cancer with bone metastasis[J].J Cancer Res Clin Oncol,2014,140(10):1769-1776.
[7] 张俊，刘增礼，崔学军，等.核素骨显像和血清PSA、ALP检测在前列腺癌骨转移诊断中的价值[J].苏州大学学报(医学版)，2007,27(3)：407-410.
[8] COOK R J,COLEMAN R,BROWN J,et al.Makers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer[J].Clin Cancer Res,2006,12(11 Pt 1):3361-3367.
[9] HORWICH A,HUGOSSON J,DE REJIKE T,et al.Prostate cancer:ESMO consensus conference guidelines 2012[J].Ann Oncol,2013,24(5):1141-1162.
[10] BERCHEM G J,BOSSELER M,MINE N,et al.Nanomolar range docetaxel treatment sensitizes MCF-7 cells to chemotherapy induced apoptosis,induces G2M arrest and phosphorylates bcl-2[J].Anticancer Res,1999,19(1A):535-540.
[11] KARABULUT B,ERTEN C,GUL M K,et al.Docetaxel/zoledronic acid combination triggers apoptosis synergistically through downregulating antiapoptotic Bcl-2 protein level in hormone-refractory prostate cancer cells[J].Cell Biology Int,2009,33(2):239-246.
[12] 余景星,刘心,徐波.多西他赛诱导HL-60/ADR细胞凋亡及对P-gp、BCL-2、BAX蛋白表达的影响[J].中国实验血液学杂志,2010,18(2):311-316.
[13] JOHANSEN J S,BRASSO K,IVERSEN P,et al.Changes of biochemical markers of bone turnover and YKL-40 following hormonal treatment for metastatic prostate cancer are related to survival[J].Clin Cancer Res,2007,13(11):3244-3249.
[14] COLLETTE L.Prediction of survival of metastatic prostate cancer based on early serial measurements of prostate specific antigen and alkaline phosphatase-Comment[J].J Urology,2008,179(1):122-122.
[15] SCHR DER F H,TOMBAL B,MILLER K,et al.Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide:results from a 12-month,comparative,phase Ⅲ study[J].Bju Int,2010,106(2):182-187.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录